Search Results - "BRAMWELL, V. H. C"

Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials by Hilton, J. F., Bouganim, N., Dong, B., Chapman, J. W., Arnaout, A., O’Malley, F., Gelmon, K. A., Yerushalmi, R., Levine, M. N., Bramwell, V. H. C., Whelan, T. J., Pritchard, K. I., Shepherd, L. E., Clemons, M.

“…The AJCC staging criteria consider tumor size to be the largest dimension of largest tumor. Some case series suggest using summation of all tumor dimensions in…”
Get full text

Expression of both Estrogen Receptor-beta 1 (ER-β1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with Estrogen Receptor-alpha (ER-α)-Negative Early Breast Cancer (EBC) by Yan, Y., Li, X., Blanchard, A., Bramwell, V.H.C., Pritchard, K.I., Tu, D., Shepherd, L., Myal, Y., Penner, C., Watson, P.H., Leygue, E., Murphy, L.C.

“…Roles of Estrogen Receptor-beta 1 (ER-β1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) in breast cancer remain unclear. Previously, ER-β1…”
Get full text

A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12) by Bramwell, V.H.C., Pritchard, K.I., Tu, D., Tonkin, K., Vachhrajani, H., Vandenberg, T.A., Robert, J., Arnold, A., O'Reilly, S.E., Graham, B., Shepherd, L.

“…In the early 1990s, the role of adjuvant tamoxifen in premenopausal women with early breast cancer (EBC) was not established. Similarly, optimum timing…”
Get full text

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials by Yerushalmi, R., Dong, B., Chapman, J.W., Goss, P.E., Pollak, M.N., Burnell, M.J., Levine, M.N., Bramwell, V.H.C., Pritchard, K.I., Whelan, T.J., Ingle, J.N., Shepherd, L.E., Parulekar, W.R., Han, L., Ding, K., Gelmon, K.A.

“…We hypothesized that increased baseline BMI and BMI change would negatively impact clinical outcomes with adjuvant breast cancer systemic therapy. Data from…”
Get full text

Do authors of review articles use systematic methods to identify, assess and synthesize information? by Bramwell, V. H. C., Williams, C. J.

“…Purpose Review articles are an important source of summary information for practising clinicians to assist them in remaining current with the rapidly expanding…”
Get full text

Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma by Bramwell, V H C, Anderson, D, Charette, M L

“…Considerable controversy exists as to whether any benefit of doxorubicin-based combination chemotherapy outweighs increased toxic effects, inconvenience, and…”
Get more information

Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma by Bramwell, V H, Eisenhauer, E A, Blackstein, M, Boos, G, Knowling, M, Jolivet, J, Bogues, W

“…New drugs are needed for treatment of unresectable or metastatic soft tissue sarcoma. Topotecan, a semisynthetic derivative of the alkaloid, camptothecin,…”
Get more information

A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma by Gortzak, E, Azzarelli, A, Buesa, J, Bramwell, V.H.C, van Coevorden, F, van Geel, A.N, Ezzat, A, Santoro, A, Oosterhuis, J.W, van Glabbeke, M, Kirkpatrick, A, Verweij, J

“…The aim of this study was to examine the strategy, feasibility and outcome of neo-adjuvant chemotherapy, with doxorubicin and ifosfamide, in adult patients…”
Get full text

Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group by Pinedo, H M, Bramwell, V H, Mouridsen, H T, Somers, R, Vendrik, C P, Santoro, A, Buesa, J, Wagener, T, van Oosterom, A T, van Unnik, J A

“…Two hundred forty-six adults with advanced progressive soft tissue sarcoma received combination chemotherapy with cyclophosphamide, vincristine, Adriamycin…”
Get more information

Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup by Souhami, R L, Craft, A W, Van der Eijken, J W, Nooij, M, Spooner, D, Bramwell, V H, Wierzbicki, R, Malcolm, A J, Kirkpatrick, A, Uscinska, B M, Van Glabbeke, M, Machin, D

“…A previous trial by the European Osteosarcoma Intergroup (EOI) suggested that a short intensive chemotherapy regimen with doxorubicin and cisplatin might…”
Get more information

Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study by Nooij, M.A., Whelan, J., Bramwell, V.H.C., Taminiau, A.T., Cannon, S., Hogendoorn, P.C.W., Pringle, J., Uscinska, B.M., Weeden, S., Kirkpatrick, A., Glabbeke, M.v., Craft, A.W.

“…There are limited data that define the role of chemotherapy in the treatment of high-grade spindle cell sarcomas of bone, other than osteosarcoma or malignant…”
Get full text

A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup by Bramwell, V H, Burgers, M, Sneath, R, Souhami, R, van Oosterom, A T, Voûte, P A, Rouesse, J, Spooner, D, Craft, A W, Somers, R

“…A randomized pilot study was undertaken to assess the acute and chronic toxicities of two short intensive chemotherapy regimens, and to evaluate the…”
Get more information

Neoadjuvant Chemotherapy With Doxorubicin and Cisplatin in Malignant Fibrous Histiocytoma of Bone: A European Osteosarcoma Intergroup Study by BRAMWELL, V. H. C, STEWARD, W. P, USCINSKA, B, KIRKPATRICK, A. L, MACHIN, D, VAN GLABBEKE, M. M, NOOIJ, M, WHELAN, J, CRAFT, A. W, GRIMER, R. J, TAMINAU, A. H. M, CANNON, S. R, MALCOLM, A. J, HOGENDOORN, P. C. W

“…Studies involving small case series have suggested that malignant fibrous histiocytoma of bone (MFH-B) is a chemosensitive tumor and that chemotherapy may…”
Get full text

Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study. Commentary by NOOIJ, M. A, WHELAN, J, GLABBEKE, M. V, CRAFT, A. W, VERWEIJ, Jaap, BRAMWELL, V. H. C, TAMINIAU, A. T, CANNON, S, HOGENDOORN, P. C. W, PRINGLE, J, USCINSKA, B. M, WEEDEN, S, KIRKPATRICK, A

Get full text

Osteosarcoma. Commentary by WHELAN, J. S, BRAMWELL, V. H. C

Get full text

Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases by Saad, Zahida, Bramwell, Vivien HC, Wilson, Sylvia M, O'Malley, Frances P, Jeacock, Julie, Chambers, Ann F

“…Retrospective studies show significant improvements in survival among women who had breast cancer resected during the luteal phase of their menstrual cycle…”
Get full text

The role of chemotherapy in osteogenic sarcoma by Bramwell, Vivien H.C.

Get full text

Pyomyositis after chemotherapy for breast cancer by KEITH, B. D, BRAMWELL, V. H. C

“…Pyomyositis is a rare complication of chemotherapy. A 47-year-old woman with metastatic breast cancer, in whom pyomyositis developed after chemotherapy, is…”
Get full text

Escalated as Compared with Standard Doses of Doxorubicin in BACOP Therapy for Patients with Non-Hodgkin's Lymphoma by Meyer, Ralph M, Quirt, Ian C, Skillings, Jamey R, Cripps, M.C, Bramwell, Vivien, Weinerman, Brian H, Gospodarowicz, Mary K, Burns, Bruce F, Sargeant, Ann Marie, Shepherd, Lois E, Zee, Benny, Hryniuk, William M

“…In treating patients with cancer, the dose intensity of chemotherapeutic drugs, defined as the dose of drug per unit of time, may be a determinant of their…”
Get full text

Chemotherapy for metastatic soft tissue sarcomas - another full circle? by BRAMWELL, V. H. C

Get full text